What is the recommended management for a patient with frequent headaches (≥2–3 days per week or >15 days per month)?

Management of Frequent Headaches (≥2-3 Days Per Week)

Patients with frequent headaches (≥2-3 days per week or >15 days per month) require immediate evaluation for preventive therapy and must be screened for medication overuse headache, which is a critical cause of headache chronification and treatment failure. 1

Step 1: Screen for Medication Overuse Headache (MOH)

This is your first priority before initiating any treatment plan. MOH is defined as headache occurring ≥15 days per month for at least 3 months in patients with pre-existing headache disorder who overuse acute medications 2, 3:

• Simple analgesics/NSAIDs: ≥15 days per month
• Triptans, ergots, opioids, or combination analgesics: ≥10 days per month

High-risk factors for MOH (assess these systematically) 4:

• Headache frequency ≥7 days/month
• Migraine diagnosis
• Frequent use of anxiolytics, analgesics, or sedative-hypnotics
• History of anxiety/depression
• Physical inactivity
• Smoking

If MOH is Present:

Immediate action required 3:

1. Education and counseling - First-line intervention explaining the medication-headache cycle
2. Abrupt withdrawal for simple analgesics, NSAIDs, triptans, or ergots
3. Slow tapering (possibly inpatient) for opioids, barbiturates, or benzodiazepines to prevent acute withdrawal
4. Initiate preventive therapy simultaneously with withdrawal

Step 2: Initiate Preventive Therapy

All patients with frequent headaches (≥2 days per month causing disability) qualify for preventive therapy 1. The generally accepted indications are:

• Two or more attacks per month producing disability lasting ≥3 days per month
• Use of abortive medication more than twice per week
• Contraindication to or failure of acute treatments
• Presence of uncommon migraine conditions (hemiplegic migraine, prolonged aura, migrainous infarction)

First-Line Preventive Agents:

Choose from these evidence-based options 1:

• Propranolol 80-240 mg/day
• Timolol 20-30 mg/day
• Amitriptyline 30-150 mg/day
• Divalproex sodium 500-1500 mg/day
• Sodium valproate 800-1500 mg/day (contraindicated in women of childbearing potential)
• Topiramate (effective for episodic and chronic migraine) 4, 5
• Candesartan or telmisartan (angiotensin receptor blockers) 4, 5

Critical prescribing principles 1:

• Start with LOW dose and titrate slowly
• Allow 2-3 months for clinical benefit to manifest - each treatment needs an adequate trial
• Avoid interfering medications (overused acute medications)
• After stability, consider tapering or discontinuing

Second-Line Preventive Agents:

If first-line agents fail 5:

• Flunarizine
• Amitriptyline (if not already tried)
• Sodium valproate (men only)

Third-Line/Newer Preventive Agents:

CGRP monoclonal antibodies - for patients who have failed multiple preventive medications 4, 5:

• Erenumab, fremanezumab, galcanezumab (strong recommendation for episodic or chronic migraine) 4
• Eptinezumab IV (weak recommendation) 4

OnabotulinumtoxinA - specifically for chronic migraine only (≥15 headache days/month), not episodic migraine 4

Step 3: Optimize Acute Treatment Strategy

While preventive therapy is being established, optimize acute treatment to prevent medication overuse 1, 6:

For Mild-to-Moderate Attacks:

First-line: NSAIDs (aspirin, ibuprofen, naproxen sodium) or acetaminophen + aspirin + caffeine combination 1

For Moderate-to-Severe Attacks or NSAID Failures:

Use combination therapy 6:

• Triptan + NSAID or Triptan + acetaminophen (most effective approach)
• Evidence supports: sumatriptan, rizatriptan, zolmitriptan, naratriptan, eletriptan, frovatriptan 1, 7, 4

Alternative options if triptans fail or contraindicated 6:

• CGRP antagonists (gepants): rimegepant, ubrogepant, zavegepant
• Ergot alkaloid: dihydroergotamine (DHE)
• Ditan: lasmiditan (last resort if all others fail)

Critical Acute Treatment Principles:

• Treat early - begin treatment as soon as headache starts 6
• Limit frequency - use acute medications <10 days/month for triptans, <15 days/month for NSAIDs to prevent MOH 6
• Never use opioids or butalbital for acute migraine treatment 6
• For nausea/vomiting: use nonoral triptan formulations + antiemetic 1

Step 4: Address Comorbidities and Triggers

Common pitfall: Failure to address these factors impairs treatment effectiveness 8:

• Depression and anxiety (very common comorbidities)
• Chronic musculoskeletal pain syndromes
• Substance abuse
• Sleep disorders

Lifestyle modifications (essential adjunct) 6:

• Adequate hydration
• Regular meals
• Consistent sleep schedule (7-9 hours)
• Regular moderate-to-intense aerobic exercise
• Stress management (relaxation techniques, mindfulness)
• Weight loss if overweight/obese
• Identify and avoid specific migraine triggers

Step 5: Patient Education and Monitoring

Engage patients actively in management 1:

• Explain medication-overuse headache risk and prevention
• Establish realistic expectations about treatment timeline (2-3 months for preventive benefit)
• Use headache diary to track:
  • Attack frequency, severity, duration
  • Resulting disability
  • Medication use and response
  • Adverse effects
  • Triggers

Schedule regular follow-up to monitor progress and adjust therapy 8

Common Pitfalls to Avoid:

1. Not screening for medication overuse - this is the most common reason for treatment failure in frequent headaches
2. Abandoning preventive therapy too early - must allow 2-3 months for benefit
3. Using opioids or butalbital - these worsen outcomes and increase MOH risk
4. Not limiting acute medication frequency - leads to MOH and chronification
5. Ignoring comorbid conditions - depression, anxiety, and chronic pain must be addressed
6. Inadequate patient education - patients must understand the treatment rationale and timeline

Special Considerations:

Women of childbearing potential/pregnancy 6:

• Discuss adverse effects of medications during pregnancy and lactation
• Avoid valproate (teratogenic - neural tube defects)
• Consider pregnancy-safe options: certain beta-blockers, magnesium

Cost considerations 6:

• Prescribe less costly recommended medications when equally effective
• CGRP antibodies and newer agents have significantly higher costs (annualized $5,000-$9,000)